AstraGin®
50 mg of AstraGin® in both APEX and RESET — the patented Astragalus and Panax notoginseng extract that upregulates intestinal transporter proteins to with manufacturer research suggesting improved bioavailability of select nutrients by up to 67% in preclinical models, ensuring the rest of the formula is actually absorbed.
Primacy Research
What AstraGin® Does For You
Intestinal Transporter Upregulation
Upregulates mRNA expression of SGLT1, PepT1, and CAT1 transporters on the intestinal brush border — increasing the total active transport capacity for amino acids, peptides, vitamins, and other nutrients per unit of intestinal surface area.
Up to 67% Absorption Enhancement
Manufacturer research reports absorption improvements of up to 67% for L-arginine (CAT1 pathway), 58% for omega-3 DHA, 51% for folate, 61% for CoQ10, and 33% for creatine — amplifying the effective dose of co-ingredients without increasing amounts.
Gut Health & Tight Junction Support
Reduces intestinal inflammation markers (TNF-α) and supports tight junction protein expression (claudin-1, occludin) — maintaining the absorptive environment that high transporter expression requires to function optimally.
Dual AM/PM Dosing Architecture
50 mg in both APEX and RESET ensures transporter upregulation is active at each separate dosing event. The 8–12 hour gap between AM and PM doses means a single-product dose cannot cover both absorption windows.
Formula-Wide Force Multiplier
A 33–67% absorption improvement for tested nutrients (arginine, DHA, folate, CoQ10, creatine) is economically equivalent to substantially increasing the effective dose of those co-ingredients — the highest-leverage infrastructure investment in the protocol.
Most of Your Supplements Are Going to Waste
Bioavailability is the percentage of an ingested compound that reaches systemic circulation in an active form. For many nutrients, this number is shockingly low: L-arginine (variable oral bioavailability, often limited by gut arginase activity), omega-3s (variable and absorption-dependent), folate (50–98% depending on food matrix), CoQ10 (poorly absorbed from most formulations). A supplement formula with 28 active ingredients is only as effective as what actually gets absorbed. Without active transport optimization, most of the formula passes through the gut without contributing to the mechanisms it was designed to support.
Transporter Decline
Intestinal transporter protein expression decreases with age, inflammation, and poor gut health. SGLT1 (glucose/amino acid transporter), PepT1 (dipeptide transporter), and CAT1 (cationic amino acid transporter for arginine) are all subject to downregulation. Lower transporter density means lower absorption capacity — regardless of how much of a compound is present in the gut lumen.
Gut Inflammation Impairs Absorption
Low-grade intestinal inflammation — increasingly common in modern populations due to processed food diets, stress, and microbiome dysbiosis — directly impairs tight junction integrity and reduces transporter expression. Inflammatory cytokines (TNF-α, IL-6) downregulate key intestinal transporters, creating an absorption penalty that undermines even high-quality supplement formulations.
The Tight Junction Paradox
Tight junctions between intestinal epithelial cells regulate paracellular permeability. Paradoxically, both impaired tight junctions (leaky gut, excess paracellular passage of undigested material) and over-tight junctions (reduced transcellular transport surface) can impair nutrient absorption. AstraGin®’s mechanism specifically targets the transporter-mediated transcellular absorption pathway — the route responsible for active, high-efficiency nutrient uptake.
How AstraGin® Works
AstraGin® is a standardized extract combining Astragalus membranaceus root and Panax notoginseng root in a patented ratio developed by NuLiv Science. Its active ginsenosides and astragalosides upregulate intestinal transporter mRNA expression — increasing the number of transporter proteins on the intestinal cell surface and accelerating active nutrient absorption.
mRNA Upregulation of Intestinal Transporters
AstraGin®’s active compounds increase mRNA expression of SGLT1 (sodium-glucose linked transporter 1), PepT1 (peptide transporter 1), and CAT1 (cationic amino acid transporter 1). Higher mRNA means more transporter protein is synthesized and expressed on the intestinal brush border — increasing the total capacity for active nutrient uptake per unit of intestinal surface area.
SGLT1 Upregulation: Glucose and Amino Acid Transport
SGLT1 is responsible for the active transport of glucose and certain amino acids across the intestinal epithelium. AstraGin®’s upregulation of SGLT1 expression increases the capacity for amino acid co-transport — relevant for the uptake of multiple amino acid-derived compounds in both APEX and RESET, including precursors for neurotransmitter synthesis.
PepT1 Upregulation: Dipeptide and Short Peptide Transport
PepT1 is the primary transporter for di- and tripeptides — including bioactive peptides from hydrolyzed proteins and peptide-form supplements. Upregulation of PepT1 by AstraGin® improves absorption of peptide-bound amino acids and certain vitamins (including folate) that utilize this transporter. This is relevant for Albion® bisglycinate (a dipeptide form of magnesium and glycine) in RESET.
Gut Health and Tight Junction Support
Beyond transporter upregulation, AstraGin® has been shown to reduce intestinal inflammation markers (TNF-α) and support tight junction protein expression (claudin-1, occludin). Maintaining tight junction integrity prevents inflammatory-driven transporter downregulation, creating the protected absorptive environment that high-transporter-expression requires to function optimally.
What the Research Shows
AstraGin® is supported primarily by manufacturer-funded preclinical research (Caco-2 cell lines and animal models) and one unpublished human study demonstrating absorption enhancement across multiple nutrient classes relevant to the Primacy protocol.
NuLiv Science proprietary research (Caco-2 cell line and animal models). Absorption enhancement percentages are manufacturer-reported from internal studies; independently peer-reviewed publications confirming these specific figures are not available. 50 mg equivalent doses.
Unpublished human study (NuLiv Science, data on file). AstraGin® at 50 mg reported 33% increase in creatine absorption vs. placebo in healthy adults. Study details, sample size, and full methodology not publicly available for independent verification.
NuLiv Science preclinical research on AstraGin® mechanism of action. Manufacturer data reports mRNA upregulation of SGLT1, PepT1, and CAT1 transporters at 50 mg dose. Tight junction support and anti-inflammatory effects (reduced TNF-α) also reported at this dose.
Your Daily Dose Across APEX + RESET
Why this dose works: AstraGin® is included in both APEX and RESET at the validated 50 mg dose because each product is a separate absorption event. The transporter upregulation from the AM dose of APEX does not persist through the 8–12 hour gap to the PM dose of RESET. Including AstraGin® in both products ensures the absorption optimization is active at each dosing window — maximizing the bioavailability of all 28 active ingredients across the full protocol.
How AstraGin® Connects Across the System
AstraGin® is the absorption multiplier for the entire Primacy protocol. It does not drive a specific cognitive pathway — it amplifies the bioavailability of the ingredients that do. Its value is proportional to the quality and quantity of the co-ingredients it serves.
AM Absorption Engine
AstraGin® in APEX upregulates CAT1 for arginine transport (amplifying NooLVL®’s NO substrate delivery), SGLT1 for amino acid transport (relevant to tyrosine for catecholamine synthesis), and general absorptive capacity for all 14 active APEX ingredients. The +67% arginine absorption improvement is particularly significant — NooLVL® already uses inositol stabilization to bypass arginase; AstraGin® then ensures maximum intestinal uptake of the bioavailable arginine that reaches the gut wall.
PM Absorption Engine
AstraGin® in RESET upregulates PepT1 for Albion® bisglycinate absorption (delivering both magnesium and glycine via dipeptide transport), supports DHA uptake from AvailOm® (via the +58% omega-3 absorption effect), and improves CoQ10 and folate absorption. RESET’s overnight recovery stack is only as effective as what actually gets into systemic circulation — AstraGin® ensures the PM formula operates at full bioavailability.
Force Multiplier Across Protocol
The economic logic of AstraGin® is asymmetric: 50 mg of AstraGin® costs far less than the active ingredients it amplifies, but a 33–67% improvement in absorption is equivalent to increasing the effective dose of every co-ingredient by that percentage. In a 28-ingredient formula, suboptimal absorption is a system-wide tax. AstraGin®’s inclusion in both products is the highest-leverage infrastructure investment in the protocol.
Key Takeaways
Bioavailability Is the Hidden Rate-Limiter
A supplement formula with premium ingredients is only as effective as what gets absorbed. Transporter protein expression is the intestinal bottleneck — and AstraGin® directly upregulates the mRNA that drives transporter synthesis. More transporters mean more of every co-ingredient reaches circulation.
+67% Arginine Absorption
The combination of NooLVL®’s inositol stabilization (bypassing gut arginase) and AstraGin®’s CAT1 upregulation (maximizing intestinal arginine transport) creates a two-stage bioavailability optimization for the NO precursor substrate. This is why APEX’s perfusion architecture uses two complementary mechanisms rather than relying on either alone.
Dose-Matched to Each Absorption Window
50 mg in APEX and 50 mg in RESET ensures transporter upregulation is active at each dosing event. The AM and PM absorption windows are separated by 8–12 hours — a single-product dose cannot cover both. AstraGin® in both products is an architectural decision, not a redundancy.
The Asymmetric ROI Ingredient
AstraGin®’s cost-to-benefit ratio is among the highest in the formula. A 50 mg dose improving absorption of 28 active ingredients by 33–67% is economically equivalent to substantially increasing the effective dose of every premium ingredient in the stack — without increasing the amount included.
Frequently Asked Questions
What is AstraGin®?
AstraGin® is a patented extract combining Astragalus membranaceus root and Panax notoginseng root, developed by NuLiv Science. Its active ginsenosides and astragalosides upregulate intestinal transporter protein expression — increasing the number of nutrient transporters on the intestinal cell surface to improve active absorption of amino acids, vitamins, omega-3s, and other nutrients.
How does AstraGin® improve absorption?
AstraGin® increases mRNA expression of key intestinal transporters: SGLT1 (sodium-glucose linked transporter for amino acids), PepT1 (peptide transporter for dipeptides like bisglycinate chelates), and CAT1 (cationic amino acid transporter for arginine). More transporter protein on the intestinal brush border means higher capacity for active nutrient uptake per unit of intestinal surface area.
Is the AstraGin® research peer-reviewed?
AstraGin® research includes Caco-2 cell line studies, animal models, and human studies conducted or commissioned by NuLiv Science. The specific absorption enhancement percentages (e.g., +67% arginine, +58% DHA) are manufacturer-reported. While the transporter upregulation mechanism is consistent with established physiology, independently peer-reviewed publications confirming these specific figures are limited. The ingredient holds over 20 patents related to its mechanism.
Why is AstraGin® in both APEX and RESET?
Each product represents a separate absorption event — the transporter upregulation from the morning APEX dose does not persist across the 8–12 hour gap to the evening RESET dose. Including AstraGin® at 50 mg in both products ensures the absorption optimization is active at each dosing window, maximizing bioavailability of all co-ingredients across the full protocol.
What APEX ingredients does AstraGin® help absorb?
In APEX, AstraGin® is most relevant for NooLVL® (arginine absorption via CAT1 upregulation — the +67% enhancement), amino acid precursors like tyrosine (for catecholamine synthesis via SGLT1), and general absorptive capacity for all 14 active ingredients including Magtein®, CognatiQ®, and BioPQQ®.
What RESET ingredients does AstraGin® help absorb?
In RESET, AstraGin® supports PepT1 upregulation for Albion® Bisglycinate absorption (delivering both magnesium and glycine via dipeptide transport), DHA uptake from AvailOm® (+58% omega-3 absorption), CoQ10 from UbiqSome® (+61%), and folate absorption. The PM formula’s overnight recovery stack depends on what actually reaches systemic circulation.
References
- [1]NuLiv Science. Proprietary Caco-2 cell line and animal model studies on AstraGin® absorption enhancement. Manufacturer data on file.
- [2]NuLiv Science. Unpublished human study: AstraGin® effect on creatine absorption in healthy adults. Data on file.
Upgrade Your Absorption Infrastructure
AstraGin® is one of 28 active ingredients across APEX and RESET, engineered to work as a system — not a stack of standalone compounds.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.